
Opinion|Videos|July 12, 2024
Where Does Axatilimab Fit in the Treatment Lineup?
Experts on graft-vs-host disease discuss the potential role for axatilimab within current treatment algorithms.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What were the key findings from the AGAVE-201 trial presented at the 2023 ASH meeting?
- How did the different dosing regimens of axatilimab compare in terms of objective response rates, duration of response, and steroid dose reduction?
- Were there any notable differences in efficacy or safety profiles observed across the different treatment arms?
- Were there any notable differences in efficacy or safety profiles observed across the different treatment arms?
- How did the different dosing regimens of axatilimab compare in terms of objective response rates, duration of response, and steroid dose reduction?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
2
Early Relapse Guides Use of CAR T vs Other Options in LBCL
3
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5











































